| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:12676599 | IVR | 20 mg/kg/day | 20 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 20 mg/kg/day | 20 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Alteration in prostate morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects expression of androgen receptor (AR) | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| PMID:17182006 | IVR | 500 mg/kg | 500 mg/kg | Decrease in cortisol levels | Neurological endocrine-mediated perturbations |
| PMID:22245120 | IVR | 100 mg/kg | 100 mg/kg | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 100 mg/kg | 100 mg/kg | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| PMID:2714525 | IVR | 0.1 mg/kg | - | No significant effects observed | - |
| IVR | 1 mg/kg | 1 mg/kg | Affects vitamin D metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Affects vitamin D metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Affects vitamin D metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Increased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 10 mg/kg | 10 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| PMID:27519288 | IVTH | 0.000000005 - 0.000005 M | 0.00000005 - 0.000005 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| PMID:28215542 | IVTH | 0.000000005 - 0.000005 M | 0.000000005 - 0.000005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:30414542 | IVTH | 0.00005 mg/L | - | No significant effects observed | - |
| IVTH | 0.0005 mg/L | - | No significant effects observed | - | |
| IVTH | 0.005 mg/L | - | No significant effects observed | - | |
| IVTH | 0.05 mg/L | - | No significant effects observed | - | |
| IVTH | 0.0000005 mg/L | 0.0000005 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.0000005 mg/L | 0.0000005 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000005 mg/L | 0.000005 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000005 mg/L | 0.000005 mg/L | Induce tumor progression | Endocrine-mediated cancer | |
| PMID:31923581 | IVTH | 0.000005 mg/L | - | No significant effects observed | - |
| IVTH | 0.0005 mg/L | 0.0005 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0005 mg/L | 0.0005 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 mg/L | 0.00005 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00005 mg/L | 0.00005 mg/L | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:3662806 | IVR | 100 mg/L | 100 mg/L | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations |
| IVR | 100 mg/L | 100 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Decrease in T4/T3 ratio | Metabolic endocrine-mediated perturbations | |
| IVR | 500 mg/L | 500 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Decrease in T4/T3 ratio | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.